☆ 4.8 Review

Treatment of extranodal NK/T-cell lymphoma: From past to future

FRONTIERS IN IMMUNOLOGY (2023)

Related references

Note: Only part of the references are listed.
Review Oncology

The efficacy of selinexor (KPT-330), an XPO1 inhibitor, on non-hematologic cancers: a comprehensive review

Jennifer R. Landes et al.

Summary: Selinexor is a novel XPO1 inhibitor that shows promise in treating solid tumors, both alone and in combination with other anticancer medications, as revealed by preclinical and clinical studies.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2023)

Add to Collection
Article Hematology

GELAD chemotherapy with sandwiched radiotherapy for patients with newly diagnosed stage IE/IIE natural killer/T-cell lymphoma: a prospective multicentre study

Yang Zhu et al.

Summary: This study evaluated the efficacy and safety of a novel chemotherapy regimen and sandwiched radiotherapy in early-stage NK/TCL patients, showing high overall response and complete response rates. With a median follow-up of 32 months, the estimated four-year overall survival and progression-free survival rates were favorable. The most common adverse events were related to pegaspargase, with mild hematological toxicities observed.

BRITISH JOURNAL OF HAEMATOLOGY (2022)

Add to Collection
Article Oncology

Characteristics and Outcome of Extranodal NK/T-cell Lymphoma in North America: A Retrospective Multi-Institutional Experience

N. Nora Bennani et al.

Summary: Extranodal natural killer/T-cell lymphoma is rare in the Western world, with most patients presenting with early-stage disease. Regardless of race/ethnicity, patients generally have poor outcomes, highlighting the need for further research and advancements in the field.

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2022)

Add to Collection
Article Immunology

Combination of Anti-PD-1 Antibody, Anlotinib and Pegaspargase Sandwich With Radiotherapy in Localized Natural Killer/T Cell Lymphoma

Peng Sun et al.

Summary: This study evaluated the efficacy and safety of a combined regimen of anti-PD-1 antibody, anlotinib, and pegaspargase sandwiched with radiotherapy in localized NKTL. The results showed a high overall response rate and complete response rate, indicating the promising effectiveness and tolerability of this treatment approach.

FRONTIERS IN IMMUNOLOGY (2022)

Add to Collection
Review Oncology

Novel Insights on the Use of L-Asparaginase as an Efficient and Safe Anti-Cancer Therapy

Maaike Van Trimpont et al.

Summary: L-asparaginase (L-ASNase) therapy is crucial for pediatric acute lymphoblastic leukemia (ALL), but its use is limited due to high toxicity. Optimized L-ASNase molecules and drug combinations offer potential solutions. Resistance mechanisms and adverse effects of L-ASNase are discussed, along with its potential for treating hematological and solid tumors.

CANCERS (2022)

Add to Collection
Article Oncology

Phase II Study of Gemcitabine, Peg-Asparaginase, Dexamethasone and Methotrexate Regimen for Newly Diagnosed Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type: Final Analysis With Long-Term Follow-Up and Rational Research for the Combination

Yu Wang et al.

Summary: This study investigated the efficacy of the GAD-M regimen in treating patients with extranodal natural killer/T-cell lymphoma (ENKTL), nasal type. The results showed that the GAD-M regimen achieved high response rates and complete remission rates in ENKTL patients. Additionally, the study found that high dose methotrexate (HD-MTX) and gemcitabine had a synergistic effect in ENKTL cells. The plasma MTX concentration ratio could also serve as an early predictor of outcomes in ENKTL.

FRONTIERS IN ONCOLOGY (2022)

Add to Collection
Article Medicine, General & Internal

Combination of atezolizumab and chidamide to maintain long-term remission in refractory metastatic extranodal natural killer/T-cell lymphoma: A case report

Juan Wang et al.

Summary: This case suggests that the combination of atezolizumab, chidamide, and radiotherapy is a promising regimen for treating refractory metastatic ENKTL following chemotherapy treatment failure.

WORLD JOURNAL OF CLINICAL CASES (2022)

Add to Collection
Article Medicine, General & Internal

Update on Molecular Diagnosis in Extranodal NK/T-Cell Lymphoma and Its Role in the Era of Personalized Medicine

Ka-Hei (Murphy) Sun et al.

Summary: Natural killer (NK)/T-cell lymphoma (NKTCL) is an aggressive malignancy with unique characteristics. Research has found that its molecular mechanisms mainly involve chromosome deletion, JAK-STAT, PD-1/PD-L1 pathways, and mutations in tumor suppressor genes. These findings could influence traditional chemoradiotherapy and provide prospects for molecular diagnosis and treatment of NKTCL.

DIAGNOSTICS (2022)

Add to Collection
Article Biology

The Pathologic and Genetic Characteristics of Extranodal NK/T-Cell Lymphoma

Hyunsung Kim et al.

Summary: Extranodal NK/T-cell lymphoma is a tumor that occurs in extranodal sites, most commonly in the nasal cavity. It is associated with the presence of the EBV genome, specific immunophenotypes, and mutations in certain pathways and genes. Understanding the molecular pathogenesis of ENKTL and developing better treatment strategies are important for managing this disease.

LIFE-BASEL (2022)

Add to Collection
Article Hematology

Naturally selected CD7 CAR-T therapy without genetic manipulations for T-ALL/LBL: first-in-human phase 1 clinical trial

Peihua Lu et al.

Summary: NS7CAR-T therapy is a safe and highly effective treatment for T-ALL/LBL, leading to minimal residual disease negative complete remission in patients. In clinical trials, no relapses were observed in 14 patients, highlighting the potential of this treatment.

BLOOD (2022)

Add to Collection
Letter Hematology

Deregulated JAK3 mediates growth advantage and hemophagocytosis in extranodal nasal-type natural killer/T-cell lymphoma

Adrien Picod et al.

HAEMATOLOGICA (2022)

Add to Collection
Article Oncology

First-Line Chemoradiation With or Without Chidamide (Tucidinostat) in Patients With Intermediate- and High-Risk Early-Stage Extranodal Nasal-Type Natural Killer/T-Cell Lymphoma: A Randomized Phase 2 Study in China

Yue Chai et al.

Summary: This study investigated the safety and efficacy of intensity-modulated radiation therapy (IMRT) followed by gemcitabine, dexamethasone, cisplatin (GDP), plus chidamide as first-line treatment for intermediate-and high-risk early-stage extranodal natural killer/T-cell lymphoma, nasal type (ENKTCL). The results showed that the addition of chidamide to IMRT + GDP achieved similar treatment outcomes and tolerable toxicities compared with IMRT + GDP alone.

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2022)

Add to Collection
Review Oncology

How we treat NK/T-cell lymphomas

Eric Tse et al.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2022)

Add to Collection
Article Oncology

A Prospective Phase II Study of Pegaspargase-COEP Plus Radiotherapy in Patients With Newly Diagnosed Extra-Nodal NK/T-Cell Lymphoma

Shaoxuan Hu et al.

Summary: This study evaluated the efficacy and safety of pegaspargase-COEP chemotherapy in combination with radiotherapy for newly diagnosed ENKTL patients. The results showed that this regimen was highly effective and safe in controlling the disease and improving overall survival.

FRONTIERS IN ONCOLOGY (2022)

Add to Collection
Article Hematology

Association of allele-specific methylation of the ASNS gene with asparaginase sensitivity and prognosis in T-ALL

Koshi Akahane et al.

Summary: Asparaginase therapy is important for T-cell acute lymphoblastic leukemia (T-ALL) patients. The methylation status of the ASNS gene is associated with asparaginase sensitivity and prognosis in T-ALL.

BLOOD ADVANCES (2022)

Add to Collection
Article Hematology

A genomic-augmented multivariate prognostic model for the survival of natural-killer/T-cell lymphoma patients from an international cohort

Jing Quan Lim et al.

Summary: We developed a genomic prognostic model (GPM) for Natural-killer/T cell lymphoma (NKTCL) using next-generation sequencing. The GPM, based on the mutational status of 13 prognostic genes, showed significant correlation with known risk-features and improved prognostication for both progression-free survival (PFS) and overall survival (OS) in NKTCL patients.

AMERICAN JOURNAL OF HEMATOLOGY (2022)

Add to Collection
Article Oncology

GEMSTONE-201: Preplanned primary analysis of a multicenter, single-arm, phase 2 study of sugemalimab (suge) in patients (pts) with relapsed or refractory extranodal natural killer/T cell lymphoma (R/R ENKTL).

Huiqiang Huang et al.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection
Review Oncology

Targeting p53-MDM2 interaction by small-molecule inhibitors: learning from MDM2 inhibitors in clinical trials

Haohao Zhu et al.

Summary: p53, encoded by TP53 gene, is a crucial tumor suppressor and can be regulated by MDM2 through negative feedback loop. Inhibiting MDM2 to restore p53 function is a hot topic in anticancer drug development. This review focuses on the discovery, structural modification, preclinical and clinical research of MDM2 inhibitors and analyzes the potential defects in their clinical development.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2022)

Add to Collection
Article Oncology

Genomic profiling identifies distinct genetic subtypes in extra-nodal natural killer/T-cell lymphoma

Gehong Dong et al.

Summary: This study provides a comprehensive genomic analysis and clinical study of extra-nodal NK/T-cell lymphoma, nasal type (ENKTCL). It identifies factors associated with overall survival, reveals frequent oncogenic activation of the JAK/STAT3 pathway, and identifies genetic clusters associated with different clinical outcomes. The study also highlights a novel functional cooperation between activating STAT3 mutations and loss of the TSG, PRDM1.

LEUKEMIA (2022)

Add to Collection
Article Oncology

Evaluation of different staging systems and prognostic analysis of nasal-type extranodal NK/T-cell lymphoma based on consistent LVDP chemotherapy regimen

Wanchun Wu et al.

Summary: This study evaluated the staging systems for nasal-type ENKTL and found that the CA staging system (CASS) had better prognostic value in survival analysis compared to the Ann Arbor staging system (AASS).

TRANSLATIONAL ONCOLOGY (2022)

Add to Collection
Article Oncology

Efficacy and Safety of a Pegasparaginase-Based Chemotherapy Regimen vs an L-asparaginase-Based Chemotherapy Regimen for Newly Diagnosed Advanced Extranodal Natural KiIler/T-Cell Lymphoma A Randomized Clinical Trial

Xinhua Wang et al.

Summary: This study compared the efficacy and safety of the DDGP regimen with the SMILE regimen in newly diagnosed advanced-stage ENKL patients. The DDGP regimen showed better progression-free survival, overall survival, and overall response rate compared to the SMILE regimen. However, the SMILE regimen had higher rates of hematologic toxic effects.

JAMA ONCOLOGY (2022)

Add to Collection
Article Oncology

Identification and Targeting of the Developmental Blockade in Extranodal Natural Killer/T-cell Lymphoma

Bethany L. Mundy-Bosse et al.

Summary: Through epigenetic and transcriptomic analyses, we found that extreme DNA hypermethylation affects genes required for NK-cell development in ENKTL. Disrupting this epigenetic blockade in novel PDX models leads to ENKTL differentiation and improved survival.

BLOOD CANCER DISCOVERY (2022)

Add to Collection
Article Medicine, Research & Experimental

DDGP vs. SMILE in Relapsed/Refractory Extranodal Natural Killer/T-cell Lymphoma, Nasal Type: A Retrospective Study of 54 Patients

Xin Wang et al.

Summary: The study compared the clinical efficacy and safety of DDGP and SMILE regimens for treating relapsed/refractory ENKL, finding that DDGP treatment resulted in higher complete response rate and better 5-year survival rates compared to SMILE. Post-treatment EBV-DNA status was identified as a significant prognostic factor for PFS and OS in relapsed/refractory ENKL.

CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2021)

Add to Collection
Article Oncology

Radiotherapy vs sequential pegaspargase, gemcitabine, cisplatin and dexamethasone and radiotherapy in newly diagnosed early natural killer/T-cell lymphoma: A randomized, controlled, open-label, multicenter study

Lei Zhang et al.

Summary: This study compared the efficacy and safety of RT and DDGP combined with RT in newly diagnosed stage I-II NKTL patients. DDGP combined with RT showed superior CRR, ORR, 5-year PFS, and OS rates compared to RT alone, but also had more side effects.

INTERNATIONAL JOURNAL OF CANCER (2021)

Add to Collection
Article Oncology

Progression-free survival at 24 months and subsequent survival of patients with extranodal NK/T-cell lymphoma: a China Lymphoma Collaborative Group (CLCG) study

Yong Yang et al.

Summary: Limited evidence supports the use of early endpoints to evaluate the success of initial treatment of ENKTCL. Analysis of a large cohort revealed that patients achieving PFS24 had a higher overall survival rate than those who did not, suggesting PFS24 may be useful for study design and risk stratification in ENKTCL.

LEUKEMIA (2021)

Add to Collection
Review Hematology

The optimal timing of radiotherapy in the combination treatment of limited-stage extranodal natural killer/T-cell lymphoma, nasal type: an updated meta-analysis

Yue Cui et al.

Summary: For patients with limited-stage extranodal natural killer/T-cell lymphoma nasal type (LS-ENKTL), upfront radiotherapy significantly prolonged overall survival and progression-free survival compared to late radiotherapy in combination with chemotherapy, with a higher complete remission rate. Patients in both groups experienced similar local recurrence-free survival, objective response rates, and toxicity.

ANNALS OF HEMATOLOGY (2021)

Add to Collection
Article Biophysics

Open-label, single arm, multicenter phase II study of VIDL induction chemotherapy followed by upfront autologous stem cell transplantation in patients with advanced stage extranodal NK/T-cell lymphoma

Ga-Young Song et al.

Summary: The study suggests that VIDL induction chemotherapy followed by upfront ASCT is effective for treating advanced-stage ENKTL, but further attention is needed in preventing CNS relapse in the treatment.

BONE MARROW TRANSPLANTATION (2021)

Add to Collection
Meeting Abstract Hematology

XPO1 Inhibitor (ATG-010) Plus Chemotherapy per Investigator's Choice for Heavily Pretreated Patients with Relapsed or Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL) and Extranodal NK/T-Cell Lymphoma (ENKTL):: Preliminary Results from a Multicenter, Single-Arm, Phase Ib Study (TOUCH Trial)

Huiqiang Huang et al.

BLOOD (2021)

Add to Collection
Article Oncology

Efficacy of Decitabine plus Anti-PD-1 Camrelizumab in Patients with Hodgkin Lymphoma Who Progressed or Relapsed after PD-1 Blockade Monotherapy

Chunmeng Wang et al.

Summary: Decitabine plus camrelizumab shows high response rates and long-term benefits in patients with relapsed/refractory cHL who failed PD-1 inhibitors, with a durable response observed in approximately 78% of patients achieving complete response at 24 months. The increase in circulating peripheral central memory T cells after treatment correlates with clinical response and progression-free survival.

CLINICAL CANCER RESEARCH (2021)

Add to Collection
Review Oncology

Modern Radiation Therapy for Extranodal Nasal-Type NK/T-cell Lymphoma: Risk-Adapted Therapy, Target Volume, and Dose Guidelines from the International Lymphoma Radiation Oncology Group

Shu-Nan Qi et al.

Summary: This article discusses the multidisciplinary management of early-stage ENKTCL, emphasizing the role of radiation therapy and nonanthracycline-based chemotherapy in improving treatment outcomes. Target volume definition, dose, and delivery methods for radiation therapy are crucial for optimizing cure in patients with early-stage ENKTCL. Risk-adapted therapy is important for individualized treatment based on the heterogeneity of clinical features.

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2021)

Add to Collection
Article Oncology

Daratumumab monotherapy for patients with relapsed or refractory natural killer/T-cell lymphoma, nasal type: an open-label, single-arm, multicenter, phase 2 study

Huiqiang Huang et al.

Summary: In this study, daratumumab monotherapy showed an overall response rate of 25.0% in patients with relapsed or refractory NKTCL. However, no patients achieved complete response, and the duration of response was short. Adverse events were manageable and there were no new safety concerns identified.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)

Add to Collection
Article Oncology

The Clinical Features and Survival Outcome of 107 Newly Diagnosed Advanced Stage Extranodal NK/T-Cell Lymphoma Cases: A Triple-Center Study

Jiwei Li et al.

Summary: Advanced stage extranodal natural killer/T-cell lymphoma (ENKTL) is a distinct type of non-Hodgkin lymphoma with poor prognosis. This study investigated clinical features, treatment strategies, and survival outcomes in 107 patients with advanced stage ENKTL. L-asparaginase-containing chemotherapy showed significantly higher 3-year progression-free survival and overall survival rates compared to CHOP, but also had more frequent grade 3/4 toxicities.

CANCER MANAGEMENT AND RESEARCH (2021)

Add to Collection
Article Oncology

Treatment, Survival, and Prognosis of Advanced-Stage Natural Killer/T-Cell Lymphoma: An Analysis From the China Lymphoma Collaborative Group

Weiping Liu et al.

Summary: This study retrospectively analyzed data from advanced-stage NKTCL patients in China and found that Asp-containing chemotherapy could improve overall survival and progression-free survival rates, indicating the need for future research and refinement of treatment models.

FRONTIERS IN ONCOLOGY (2021)

Add to Collection
Article Oncology

A Multi-Center, Real-World Study of Chidamide for Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas in China

Weiping Liu et al.

Summary: A multi-center observational study in China evaluated the efficacy and safety of chidamide treatment for patients with relapsed/refractory PTCL. The study showed that chidamide monotherapy and combination therapies both improved objective response rate and overall survival, with a significant survival advantage compared to international historical records. The most common adverse effects were hematological toxicities, mostly mild to moderate in severity. Further research should investigate the potential benefits of combining chidamide treatment with chemotherapy.

FRONTIERS IN ONCOLOGY (2021)

Add to Collection
Review Oncology

EBV and the Pathogenesis of NK/T Cell Lymphoma

Ivonne A. Montes-Mojarro et al.

Summary: ENKTCL is an aggressive lymphoma associated with EBV infection, characterized by activation of the JAK-STAT pathway and mutations in genes like BCOR, DDX3X and TP53. Differences in EBV strains and LMP1 variants among populations provide insights into the pathogenesis and genetics of ENKTCL. The genetic landscape of ENKTCL highlights mechanisms of lymphomagenesis and potential therapeutic targets.

CANCERS (2021)

Add to Collection
Article Hematology

Sequential P-GEMOX and radiotherapy for early-stage extranodal natural killer/T-cell lymphoma: A multicenter study

Yuchen Zhang et al.

Summary: This study reported the efficacy and toxicity of sequential P-GEMOX and radiotherapy in early-stage ENKTL patients, showing a high overall response rate and complete remission rate, with good survival outcomes. The treatment was well-tolerated and manageable, indicating it as an effective therapeutic option for early-stage ENKTL patients.

AMERICAN JOURNAL OF HEMATOLOGY (2021)

Add to Collection
Article Hematology

Autologous EBV-specific T cell treatment results in sustained responses in patients with advanced extranodal NK/T lymphoma: results of a multicenter study

Won Seog Kim et al.

Summary: The study conducted a phase II clinical trial of autologous EBV-specific T cell treatment (baltaleucel-T) in advanced, relapsed ENKTL patients. The results showed that this treatment demonstrated single-agent activity and improved survival outcomes in some patients.

ANNALS OF HEMATOLOGY (2021)

Add to Collection
Article Hematology

A PHASE I B STUDY OF AN ORAL PI3Kδ INHIBITOR LINPERLISIB IN PATIENTS WITH RELAPSED OR REFRACTORY PERIPHERAL T CELL LYMPHOMA

L. Qiu et al.

HEMATOLOGICAL ONCOLOGY (2021)

Add to Collection
Review Microbiology

Extranodal NK/T-Cell Lymphoma, Nasal Type: Genetic, Biologic, and Clinical Aspects with a Central Focus on Epstein-Barr Virus Relation

Miki Takahara et al.

Summary: ENKTL-NT is commonly seen in Eastern Asia, with progressive necrotic lesions and poor prognosis. Diagnosis of ENKTL-NT requires CD56 immunostaining and EBER in situ hybridization, while monitoring can be done through serum EBV DNA levels. Despite being refractory, therapies such as concomitant chemoradiotherapy have improved the prognosis of ENKTL-NT.

MICROORGANISMS (2021)

Add to Collection
Article Oncology

Phase II study of sequential chemoradiotherapy with L-asparaginase, dexamethasone, ifosfamide, cisplatin, and etoposide (DICE-L) in the early stage of extranodal natural killer (NK)/T-cell lymphoma

Yao Zhang et al.

Summary: The study suggests that sequential chemoradiotherapy using the DICE-L regimen followed by radiotherapy is an effective treatment modality for newly diagnosed stage I and II ENKTL patients, with a CR rate of 84% and 5-year survival rates of 82.4% and 63.4% respectively.

ANNALS OF TRANSLATIONAL MEDICINE (2021)

Add to Collection
Article Oncology

Association of improved overall survival with decreased distant metastasis following asparaginase-based chemotherapy and radiotherapy for intermediate- and high-risk early-stage extranodal nasal-type NK/T-cell lymphoma: a CLCG study

X. Zheng et al.

Summary: This study evaluated the survival benefit of ASP-based versus non-ASP-based chemotherapy combined with radiotherapy in patients with early-stage ENKTCL. ASP-based regimens significantly improved 5-year overall survival and distant metastasis-free survival for intermediate- and high-risk patients, but not for low-risk patients. The findings support ASP-based chemotherapy and radiotherapy as a first-line treatment strategy for intermediate- and high-risk early-stage ENKTCL.

ESMO OPEN (2021)

Add to Collection
Article Biochemistry & Molecular Biology

Sintilimab for relapsed/refractory extranodal NK/T cell lymphoma: a multicenter, single-arm, phase 2 trial (ORIENT-4)

Rong Tao et al.

Summary: The study demonstrated that sintilimab is effective and well tolerated in patients with relapsed/refractory extranodal NK/T cell lymphoma, with a low rate of adverse events. It could be a novel therapeutic approach for controlling this type of cancer.

SIGNAL TRANSDUCTION AND TARGETED THERAPY (2021)

Add to Collection
Article Oncology

Epidemiology and Clinical Characteristics of Non-Hodgkin Lymphoma in Mexico

Eleazar Hernandez-Ruiz et al.

Summary: This study conducted a retrospective, descriptive analysis of non-Hodgkin lymphoma cases in 14 hospitals across Mexico. The most common histological subtype for B-cell lymphomas was found to be diffuse large B-cell lymphoma, while for T-cell lymphoma, the NK/T histological subtype was the most frequent. The treatment regimens and radiotherapy rates differed between the two types of lymphomas, with B-cell lymphomas showing higher overall survival rates.

WORLD JOURNAL OF ONCOLOGY (2021)

Add to Collection
Article Health Care Sciences & Services

Comprehensive analysis of peripheral T-cell and natural killer/T-cell lymphoma in Asian patients: A multinational, multicenter, prospective registry study in Asia

Sang Eun Yoon et al.

Summary: This multinational, multicenter study aimed to understand the relative frequency and treatment outcomes of Peripheral T-cell lymphomas (PTCLs) in Asian patients. The study found that extranodal NK/T-cell lymphoma was the most common subtype, and anthracycline-containing chemotherapies were not satisfactory for PTCLs other than ENKTL.

LANCET REGIONAL HEALTH-WESTERN PACIFIC (2021)

Add to Collection
Review Oncology

The nuclear export protein XPO1-from biology to targeted therapy

Asfar S. Azmi et al.

Summary: XPO1 plays a crucial role in cellular homeostasis and cancer development, with its inhibitor selinexor clinically validated and approved for multiple myeloma and diffuse large B cell lymphoma treatment.

NATURE REVIEWS CLINICAL ONCOLOGY (2021)

Add to Collection
Article Hematology

Long-term eradication of extranodal natural killer/T-cell lymphoma, nasal type, by induced pluripotent stem cell-derived Epstein-Barr virus-specific rejuvenated T cells in vivo

Miki Ando et al.

HAEMATOLOGICA (2020)

Add to Collection
Article Oncology

Long-term outcomes of patients treated with an EPOCHL regimen as first-line chemotherapy for newly diagnosed extranodal natural killer/T-cell lymphoma: a retrospective single-center study

Liqiang Wei et al.

LEUKEMIA & LYMPHOMA (2020)

Add to Collection
Article Oncology

Efficacy of Brentuximab Vedotin in Relapsed or Refractory High-CD30-Expressing Non-Hodgkin Lymphomas: Results of a Multicenter, Open-Labeled Phase II Trial

Seok Jin Kim et al.

CANCER RESEARCH AND TREATMENT (2020)

Add to Collection
Article Oncology

Study of L-Asparaginase, Vincristine, and Dexamethasone Combined With Intensity-modulated Radiation Therapy in Early-Stage Nasal NK/T-Cell Lymphoma

Yunfei Hu et al.

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2020)

Add to Collection
Article Pathology

Immune subtyping of extranodal NK/T-cell lymphoma: a new biomarker and an immune shift during disease progression

Junhun Cho et al.

MODERN PATHOLOGY (2020)

Add to Collection
Letter Oncology

A proposal for a new staging system for extranodal natural killer T-cell lymphoma: a multicenter study from China and Asia Lymphoma Study Group

Huangming Hong et al.

LEUKEMIA (2020)

Add to Collection
Article Oncology

Cutaneous extranodal natural killer (NK)/T - cell lymphoma: A comprehensive clinical features and outcomes analysis of 71 cases

Li Jiang et al.

LEUKEMIA RESEARCH (2020)

Add to Collection
Article Hematology

Risk-based, response-adapted therapy for early-stage extranodal nasal-typeNK/T-cell lymphoma in the modern chemotherapy era: A China Lymphoma Collaborative Group study

Shu-Nan Qi et al.

AMERICAN JOURNAL OF HEMATOLOGY (2020)

Add to Collection
Article Hematology

Combined gemcitabine, cisplatin, dexamethasone, methotrexate, and pegaspargase (GDP-ML) for patients with newly diagnosed extranodal natural killer/T cell lymphoma, nasal type: a single arm, single center, prospective phase 2 study

Chong Wei et al.

ANNALS OF HEMATOLOGY (2020)

Add to Collection
Article Oncology

Genomic and Transcriptomic Characterization of Natural Killer T Cell Lymphoma

Jie Xiong et al.

CANCER CELL (2020)

Add to Collection
Article Hematology

Survival outcomes of patients with extranodal natural-killer T-cell lymphoma: a prospective cohort study from the international T-cell Project

Christopher P. Fox et al.

LANCET HAEMATOLOGY (2020)

Add to Collection
Article Oncology

Efficacy of B7-H3-Redirected BiTE and CAR-T Immunotherapies Against Extranodal Nasal Natural Killer/T Cell Lymphoma

Meijun Zheng et al.

TRANSLATIONAL ONCOLOGY (2020)

Add to Collection
Article Hematology

Avelumab for the treatment of relapsed or refractory extranodal NK/T-cell lymphoma: an open-label phase 2 study

Seok Jin Kim et al.

BLOOD (2020)

Add to Collection
Article Oncology

Radiotherapy followed by DICEP regimen in treatment of newly diagnosed, stage IE/IIE, extranodal NK/T-cell lymphoma patients

Yizhen Liu et al.

CANCER MEDICINE (2020)

Add to Collection
Letter Oncology

Whole-genome sequencing identifies responders to Pembrolizumab in relapse/refractory natural-killer/T cell lymphoma

Jing Quan Lim et al.

LEUKEMIA (2020)

Add to Collection
Article Medicine, General & Internal

Long-term outcomes of upfront concurrent chemoradiotherapy followed by P-GDP regimen in newly diagnosed early stage extranodal nasal-type NK/T cell lymphoma A prospective single-center phase II study

Fang Zhu et al.

MEDICINE (2020)

Add to Collection
Review Oncology

The landscape of new drugs in extranodal NK/T-cell lymphoma

Liang Wang et al.

CANCER TREATMENT REVIEWS (2020)

Add to Collection
Article Oncology

Pegaspargase Combined with Concurrent Radiotherapy forEarly-StageExtranodal Natural Killer/T-CellLymphoma, Nasal Type: ATwo-CenterPhaseIIstudy

Hua Wang et al.

ONCOLOGIST (2020)

Add to Collection
Article Oncology

Modified SMILE (mSMILE) and intensity-modulated radiotherapy (IMRT) for extranodal NK-T lymphoma nasal type in a single-center population

Paola Ghione et al.

LEUKEMIA & LYMPHOMA (2020)

Add to Collection
Article Oncology

Phase I/Ib Study of Tenalisib (RP6530), a Dual PI3K δ/γ Inhibitor in Patients with Relapsed/Refractory T-Cell Lymphoma

Auris Huen et al.

CANCERS (2020)

Add to Collection
Review Oncology

Durable Response to Sintilimab and Chidamide in a Patient With Pegaspargase- and Immunotherapy-Resistant NK/T-Cell Lymphoma: Case Report and Literature Review

Zheng Yan et al.

FRONTIERS IN ONCOLOGY (2020)

Add to Collection
Meeting Abstract Hematology

Anti-PD-1 Antibody (Sintilimab) Plus Histone Deacetylase Inhibitor (Chidamide) for the Treatment of Refractory or Relapsed Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (r/r-ENKTL): Preliminary Results from a Prospective, Multicenter, Single-Arm, Phase Ib/II Trial (SCENT)

Yan Gao et al.

BLOOD (2020)

Add to Collection
Article Biochemistry & Molecular Biology

Combination of anti-PD-1 antibody with P-GEMOX as a potentially effective immunochemotherapy for advanced natural killer/T cell lymphoma

Jun Cai et al.

SIGNAL TRANSDUCTION AND TARGETED THERAPY (2020)

Add to Collection
Article Oncology

Outcomes of patients treated with SVILE vs. P-GemOx for extranodal natural killer/T-cell lymphoma, nasal type: a prospective, randomized controlled study

Liqiang Wei et al.

CANCER BIOLOGY & MEDICINE (2020)

Add to Collection
Review Oncology

Molecular pathogenic pathways in extranodal NK/T cell lymphoma

Sanjay de Mel et al.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)

Add to Collection
Article Oncology

Gemcitabine, dexamethasone, and cisplatin (GDP) chemotherapy with sandwiched radiotherapy in the treatment of newly diagnosed stage IE/IIE extranodal natural killer/T-cell lymphoma, nasal type

Shu Tian et al.

CANCER MEDICINE (2019)

Add to Collection
Article Oncology

Upfront radiation is essential for high-risk early-stage extranodal NK/T-cell lymphoma, nasal type: comparison of two sequential treatment modalities combining radiotherapy and GDP (gemcitabine, dexamethasone, and cisplatin) in the modern era

Fei Qi et al.

LEUKEMIA & LYMPHOMA (2019)

Add to Collection
Meeting Abstract Hematology

Clinical Outcome of an Multicentre, Randomized, Phase II Clinical Trial for Patients with Extranodal NK/T Cell Lymphoma Treated By P-Gemox or Aspametdex

Hui-qiang Huang et al.

BLOOD (2019)

Add to Collection
Review Oncology

Defining the toxicity of current regimens for extranodal NK/T cell lymphoma: a systematic review and metaproportion

Vadim S. Pokrovsky et al.

EXPERT REVIEW OF ANTICANCER THERAPY (2019)

Add to Collection
Article Oncology

Comparison of chemoradiotherapy with radiotherapy alone for early-stage extranodal natural killer/T-cell lymphoma, nasal type in elderly patients

Chang Su et al.

LEUKEMIA & LYMPHOMA (2018)

Add to Collection
Article Oncology

Management of Advanced and Relapsed/Refractory Extranodal Natural Killer T-Cell Lymphoma: An Analysis of Stem Cell Transplantation and Chemotherapy Outcomes

Jonathan E. Brammer et al.

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2018)

Add to Collection
Article Hematology

Efficacy and tolerance of GELOXD/P-GEMOXD in newly diagnosed nasal-type extranodal NK/T-cell lymphoma: A multicenter retrospective study

Ji-Wei Li et al.

EUROPEAN JOURNAL OF HAEMATOLOGY (2018)

Add to Collection
Article Oncology

Phase 2 Study of First-line Intensity Modulated Radiation Therapy Followed by Gemcitabine, Dexamethasone, and Cisplatin for High-Risk, Early Stage Extranodal Nasal-Type NK/T-Cell Lymphoma: The GREEN Study

Fei Qi et al.

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2018)

Add to Collection
Article Oncology

Radiotherapy is essential after complete response to asparaginase-containing chemotherapy in early-stage extranodal nasal-type NK/T-cell lymphoma: A multicenter study from the China Lymphoma Collaborative Group (CLCG)

Xiu-Wen Deng et al.

RADIOTHERAPY AND ONCOLOGY (2018)

Add to Collection
Article Oncology

Comparison of Native Escherichia coli L-Asparaginase versus Pegylated Asparaginase, in Combination with Ifosfamide, Methotrexate, Etoposide, and Prednisolone, in Extranodal NK/T-Cell Lymphoma, Nasal Type

Hyun Jee Kim et al.

CANCER RESEARCH AND TREATMENT (2018)

Add to Collection
Article Oncology

A Multicenter Retrospective Comparison of Sequential versus Sandwich Chemoradiotherapy for Stage IE-IIE Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type

Jin Li et al.

JOURNAL OF CANCER (2018)

Add to Collection
Article Oncology

PEG-L-CHOP treatment is safe and effective in adult extranodal NK/T-cell lymphoma with a low rate of clinical hypersensitivity

Wen Zheng et al.

BMC CANCER (2018)

Add to Collection
Article Biotechnology & Applied Microbiology

Asparagine synthetase expression is associated with the sensitivity to asparaginase in extranodal natural Killer/T-cell lymphoma in vivo and in vitro

Wen-jian Liu et al.

ONCOTARGETS AND THERAPY (2018)

Add to Collection
Article Oncology

Pegaspargase, gemcitabine, dexamethasone, and cisplatin (P-GDP) combined chemotherapy is effective for newly diagnosed extranodal NK/T-cell lymphoma: a retrospective study

Tao Liu et al.

CANCER MANAGEMENT AND RESEARCH (2018)

Add to Collection
Article Oncology

IL-2Rα up-regulation is mediated by latent membrane protein 1 and promotes lymphomagenesis and chemotherapy resistance in natural killer/T-cell lymphoma

Liang Wang et al.

CANCER COMMUNICATIONS (2018)

Add to Collection
Article Hematology

Activity of the PI3K-δ,γ inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma

Steven M. Horwitz et al.

BLOOD (2018)

Add to Collection
Article Oncology

Sequential chemotherapy/radiotherapy was comparable with concurrent chemoradiotherapy for stage I/IINK/T-cell lymphoma

Y. L. Kwong et al.

ANNALS OF ONCOLOGY (2018)

Add to Collection
Article Hematology

Effectiveness of pegaspargase, gemcitabine, and oxaliplatin (P-GEMOX) chemotherapy combined with radiotherapy in newly diagnosed, stage IE to IIE, nasal-type, extranodal natural killer/T-cell lymphoma

Wen Wei et al.

HEMATOLOGY (2017)

Add to Collection
Article Oncology

A comparison of treatment modalities for nasal extranodal natural killer/T-cell lymphoma in early stages: The efficacy of CHOP regimen based concurrent chemoradiotherapy

Jianzhong Cao et al.

ONCOTARGET (2017)

Add to Collection
Article Oncology

Radiotherapy improves survival in early stage extranodal natural killer/T cell lymphoma patients receiving asparaginase-based chemotherapy

Yi-Yang Li et al.

ONCOTARGET (2017)

Add to Collection
Review Oncology

L-Asparaginase for newly diagnosed extra-nodal NK/T-cell lymphoma: systematic review and meta-analysis

Vadim S. Pokrovsky et al.

EXPERT REVIEW OF ANTICANCER THERAPY (2017)

Add to Collection
Article Oncology

Treatments and Outcomes of Patients With Extranodal Natural Killer/T-Cell Lymphoma Diagnosed Between 2000 and 2013: A Cooperative Study in Japan

Motoko Yamaguchi et al.

JOURNAL OF CLINICAL ONCOLOGY (2017)

Add to Collection
Article Oncology

Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China

Yuankai Shi et al.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)

Add to Collection
Article Biotechnology & Applied Microbiology

A systematic comparison of treatment modalities for nasal extranodal natural killer/T-cell lymphoma in early stages between concurrent chemoradiotherapy and sequential chemotherapy

Ming Qian et al.

ONCOTARGETS AND THERAPY (2017)

Add to Collection
Letter Oncology

Efficacy of pegaspargase, etoposide, methotrexate and dexamethasone in newly diagnosed advanced-stage extra-nodal natural killer/T-cell lymphoma with the analysis of the prognosis of whole blood EBV-DNA

J-H Liang et al.

BLOOD CANCER JOURNAL (2017)

Add to Collection
Article Oncology

A phase II prospective study of the Sandwich protocol, L-asparaginase, cisplatin, dexamethasone and etoposide chemotherapy combined with concurrent radiation and cisplatin, in newly diagnosed, I/II stage, nasal type, extranodal natural killer/T-cell lymphoma

Ming Jiang et al.

ONCOTARGET (2017)

Add to Collection
Article Medicine, General & Internal

A Phase II Study of Methotrexate, Etoposide, Dexamethasone and Pegaspargase Sandwiched with Radiotherapy in the Treatment of Newly Diagnosed, Stage IE to IIE Extranodal Natural-Killer/T-Cell Lymphoma, Nasal-Type

Peng-Peng Xu et al.

EBIOMEDICINE (2017)

Add to Collection
Article Oncology

Beyond first-line non-anthracycline-based chemotherapy for extranodal NK/T-cell lymphoma: clinical outcome and current perspectives on salvage therapy for patients after first relapse and progression of disease

S. H. Lim et al.

ANNALS OF ONCOLOGY (2017)

Add to Collection
Article Hematology

Intensity-modulated radiation therapy followed by GDP chemotherapy for newly diagnosed stage I/II extranodal natural killer/T cell lymphoma, nasal type

Yu Huang et al.

ANNALS OF HEMATOLOGY (2017)

Add to Collection
Article Oncology

The Impact of the Omission or Inadequate Dosing of Radiotherapy in Extranodal Natural Killer T-Cell Lymphoma, Nasal Type, in the United States

John A. Vargo et al.

CANCER (2017)

Add to Collection
Article Hematology

PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing L-asparaginase

Yok-Lam Kwong et al.

BLOOD (2017)

Add to Collection
Article Oncology

Five-year analysis from phase 2 trial of sandwich chemoradiotherapy in newly diagnosed, stage IE to IIE, nasal type, extranodal natural killer/T-cell lymphoma

Li Zhang et al.

CANCER MEDICINE (2016)

Add to Collection
Letter Hematology

Complete remission of refractory disseminated NK/T cell lymphoma with brentuximab vedotin and bendamustine

Li-Mei Poon et al.

ANNALS OF HEMATOLOGY (2016)

Add to Collection
Article Oncology

PD-L1 is upregulated by EBV-driven LMP1 through NF-κB pathway and correlates with poor prognosis in natural killer/T-cell lymphoma

Xi-wen Bi et al.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2016)

Add to Collection
Article Oncology

Sequential DICE combined with L-asparaginase chemotherapy followed by involved field radiation in newly diagnosed, stage IE to IIE, nasal and extranodal NK/T-cell lymphoma

Li-Hua Dong et al.

LEUKEMIA & LYMPHOMA (2016)

Add to Collection
Article Oncology

Clinical impact of induction treatment modalities and optimal timing of radiotherapy for the treatment of limited-stage NK/T cell lymphoma

Joon-Ho Moon et al.

LEUKEMIA RESEARCH (2016)

Add to Collection
Article Medicine, General & Internal

The Roles of Radiotherapy and Chemotherapy in the Era of Multimodal Treatment for Early-Stage Nasal-Type Extranodal Natural Killer/T-Cell Lymphoma

Tae Hyung Kim et al.

YONSEI MEDICAL JOURNAL (2016)

Add to Collection
Article Oncology

Phase II trial of concurrent chemoradiotherapy with L-asparaginase and MIDLE chemotherapy for newly diagnosed stage I/II extranodal NK/T-cell lymphoma, nasal type (CISL1008)

Dok Hyun Yoon et al.

ONCOTARGET (2016)

Add to Collection
Article Oncology

Efficacy of combined gemcitabine, oxaliplatin and pegaspargase (P-gemox regimen) in patients with newly diagnosed advanced-stage or relapsed/refractory extranodal NK/T-cell lymphoma

Jing-hua Wang et al.

ONCOTARGET (2016)

Add to Collection
Article Oncology

Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma

Y. Shi et al.

ANNALS OF ONCOLOGY (2015)

Add to Collection
Article Hematology

Risk-adapted therapy for early-stage extranodal nasal-type NK/T-cell lymphoma: analysis from a multicenter study

Yong Yang et al.

BLOOD (2015)

Add to Collection
Article Oncology

Concurrent Etoposide, Steroid, High-dose Ara-C and Platinum chemotherapy with radiation therapy in localised extranodal natural killer (NK)/T-cell lymphoma, nasal type

Jean-Marie Michot et al.

EUROPEAN JOURNAL OF CANCER (2015)

Add to Collection
Article Hematology

High-dose methotrexate, etoposide, dexamethasone and pegaspargase (MEDA) combination chemotherapy is effective for advanced and relapsed/refractory extranodal natural killer/T cell lymphoma: a retrospective study

Hao Ding et al.

INTERNATIONAL JOURNAL OF HEMATOLOGY (2015)

Add to Collection
Article Oncology

Phase 1 study of the investigational Aurora A kinase inhibitor alisertib (MLN8237) in East Asian cancer patients: pharmacokinetics and recommended phase 2 dose

Karthik Venkatakrishnan et al.

INVESTIGATIONAL NEW DRUGS (2015)

Add to Collection
Article Oncology

Phase II Intergroup Trial of Alisertib in Relapsed and Refractory Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides: SWOG 1108

Paul M. Barr et al.

JOURNAL OF CLINICAL ONCOLOGY (2015)

Add to Collection
Review Oncology

Asparaginase pharmacokinetics and implications of therapeutic drug monitoring

Barbara Asselin et al.

LEUKEMIA & LYMPHOMA (2015)

Add to Collection
Article Oncology

Trial of LVDP regimen (L-asparaginase, etoposide, dexamethasone, and cisplatin, followed by radiotherapy) as first-line treatment for newly diagnosed, stage III/IV extranodal natural killer/T cell lymphoma

Y. Q. Wang et al.

MEDICAL ONCOLOGY (2015)

Add to Collection
Article Biotechnology & Applied Microbiology

Long-term Outcome of Extranodal NK/T Cell Lymphoma Patients Treated With Postremission Therapy Using EBV LMP1 and LMP2a-specific CTLs

Seok-Goo Cho et al.

MOLECULAR THERAPY (2015)

Add to Collection
Article Genetics & Heredity

Exome sequencing identifies somatic mutations of DDX3X in natural killer/T-cell lymphoma

Lu Jiang et al.

NATURE GENETICS (2015)

Add to Collection
Review Pediatrics

Asparaginase Therapy in Pediatric Acute Lymphoblastic Leukemia: A Focus on the Mode of Drug Resistance

Shih-Hsiang Chen

PEDIATRICS AND NEONATOLOGY (2015)

Add to Collection
Article Hematology

Ifosfamide, methotrexate, etoposide, and prednisolone (IMEP) plus L-asparaginase as a first-line therapy improves outcomes in stage III/IV NK/T cell-lymphoma, nasal type (NTCL)

Miso Kim et al.

ANNALS OF HEMATOLOGY (2015)

Add to Collection
Article Hematology

Induction treatment with SMILE and consolidation with autologous stem cell transplantation for newly diagnosed stage IV extranodal natural killer/T-cell lymphoma patients

Seok Jin Kim et al.

ANNALS OF HEMATOLOGY (2015)

Add to Collection
Article Hematology

Early radiotherapy has an essential role for improving survival in patients with stage I-II nasal-type of cell lymphoma treated with lasparaginase-containing chemotherapy-a single institution experience

Jian Zang et al.

ANNALS OF HEMATOLOGY (2015)

Add to Collection
Article Hematology

Long-term results of a phase II trial with frontline concurrent chemoradiotherapy followed by consolidation chemotherapy for localized nasal natural killer/T-cell lymphoma

Hui-Jen Tsai et al.

EUROPEAN JOURNAL OF HAEMATOLOGY (2015)

Add to Collection
Article Oncology

Comparison of gemcitabine, oxaliplatin and L-asparaginase and etoposide, vincristine, doxorubicin, cyclophosphamide and prednisone as first-line chemotherapy in patients with stage IE to IIE extranodal natural killer/T-cell lymphoma: a multicenter retrospective study

Hua Wang et al.

LEUKEMIA & LYMPHOMA (2015)

Add to Collection
Article Oncology

Clinical Application of Asparaginase Activity Levels Following Treatment With Pegaspargase

Archie Bleyer et al.

PEDIATRIC BLOOD & CANCER (2015)

Add to Collection
Article Multidisciplinary Sciences

A TNM Staging System for Nasal NK/T-Cell Lymphoma

Zheng Yan et al.

PLOS ONE (2015)

Add to Collection
Letter Hematology

Complete remission in CD30-positive refractory extranodal NK/T-cell lymphoma with brentuximab vedotin

Hee Kyung Kim et al.

BLOOD RESEARCH (2015)

Add to Collection
Article Hematology

Effectiveness of gemcitabine, pegaspargase, cisplatin, and dexamethasone (DDGP) combination chemotherapy in the treatment of relapsed/refractory extranodal NK/T cell lymphoma: a retrospective study of 17 patients

Zhiyuan Zhou et al.

ANNALS OF HEMATOLOGY (2014)

Add to Collection
Article Hematology

Concurrent chemoradiotherapy followed by L-asparaginase-containing chemotherapy, VIDL, for localized nasal extranodal NK/T cell lymphoma: CISL08-01 phase II study

Seok Jin Kim et al.

ANNALS OF HEMATOLOGY (2014)

Add to Collection
Article Biophysics

Allogeneic haematopoietic SCT for natural killer/T-cell lymphoma: a multicentre analysis from the Asia Lymphoma Study Group

E. Tse et al.

BONE MARROW TRANSPLANTATION (2014)

Add to Collection
Article Oncology

Sustained Complete Responses in Patients With Lymphoma Receiving Autologous Cytotoxic T Lymphocytes Targeting Epstein-Barr Virus Latent Membrane Proteins

Catherine M. Bollard et al.

JOURNAL OF CLINICAL ONCOLOGY (2014)

Add to Collection
Article Oncology

Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification

Bruce D. Cheson et al.

JOURNAL OF CLINICAL ONCOLOGY (2014)

Add to Collection
Article Dermatology

Cutaneous extranodal natural killer/T-cell lymphoma: A comparative clinicohistopathologic and survival outcome analysis of 45 cases according to the primary tumor site

Woo Jin et al.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2014)

Add to Collection
Letter Oncology

A study of gemcitabine, L-asparaginase, ifosfamide, dexamethasone and etoposide chemotherapy for newly diagnosed stage IV, relapsed or refractory extranodal natural killer/T-cell lymphoma, nasal type

Jie Ji et al.

LEUKEMIA & LYMPHOMA (2014)

Add to Collection
Article Oncology

A Phase II Study of Ifosfamide, Methotrexate, Etoposide, and Prednisolone for Previously Untreated Stage I/II Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type: A Multicenter Trial of the Korean Cancer Study Group

Tae Min Kim et al.

ONCOLOGIST (2014)

Add to Collection
Article Oncology

Asparagine synthetase expression and its potential prognostic value in patients with NK/T cell lymphoma

Yaqing Li et al.

ONCOLOGY REPORTS (2014)

Add to Collection
Article Oncology

Concurrent IMRT and weekly cisplatin followed by GDP chemotherapy in newly diagnosed, stage IE tdso IIE, nasal, extranodal NK/T-Cell lymphoma

Q-H Ke et al.

BLOOD CANCER JOURNAL (2014)

Add to Collection
Article Hematology

Retrospective analysis of treatment outcomes for extranodal NK/T-cell lymphoma (ENKL), nasal type, stage I-IIE: single institute experience of combined modality treatment for early localized nasal extranodal NK/T-cell lymphoma (ENKL)

Jayoung Lee et al.

ANNALS OF HEMATOLOGY (2013)

Add to Collection
Article Oncology

First-line combination of gemcitabine, oxaliplatin, and L-asparaginase (GELOX) followed by involved-field radiation therapy for patients with stage IE/IIE extranodal natural killer/T-cell lymphoma

Liang Wang et al.

CANCER (2013)

Add to Collection
Article Oncology

PD-L1 Expression Is Characteristic of a Subset of Aggressive B-cell Lymphomas and Virus-Associated Malignancies

Benjamin J. Chen et al.

CLINICAL CANCER RESEARCH (2013)

Add to Collection
Article Oncology

Gemcitabine alone and/or containing chemotherapy is efficient in refractory or relapsed NK/T-cell lymphoma

Hee Kyung Ahn et al.

INVESTIGATIONAL NEW DRUGS (2013)

Add to Collection
Article Gastroenterology & Hepatology

Prognostic Characteristics of Gastrointestinal Tract NK/T-Cell Lymphoma An Analysis of 47 Patients in China

Ming Jiang et al.

JOURNAL OF CLINICAL GASTROENTEROLOGY (2013)

Add to Collection
Article Oncology

A prospective phase II study of L-asparaginase- CHOP plus radiation in newly diagnosed extranodal NK/T-cell lymphoma, nasal type

Ningjing Lin et al.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2013)

Add to Collection
Article Oncology

Combined therapy in untreated patients improves outcome in Nasal NK/T lymphoma: results of a clinical trial

Agustin Aviles et al.

MEDICAL ONCOLOGY (2013)

Add to Collection
Article Hematology

Sequential chemotherapy followed by radiotherapy versus concurrent chemoradiotherapy in patients with stage I/II extranodal natural killer/T-cell lymphoma, nasal type

Jieun Lee et al.

BLOOD RESEARCH (2013)

Add to Collection
Article Hematology

Dexamethasone exposure and asparaginase antibodies affect relapse risk in acute lymphoblastic leukemia

Jitesh D. Kawedia et al.

BLOOD (2012)

Add to Collection
Article Oncology

Phase 2 trial of Sandwich L-asparaginase, vincristine, and prednisone chemotherapy with radiotherapy in newly diagnosed, stage IE to IIE, nasal type, extranodal natural killer/T-cell lymphoma

Ming Jiang et al.

CANCER (2012)

Add to Collection
Article Hematology

Cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) in the treatment of stage IE/IIE extranodal natural killer/T cell lymphoma, nasal type: 13-year follow-up in 135 patients

Liang Wang et al.

INTERNATIONAL JOURNAL OF HEMATOLOGY (2012)

Add to Collection
Letter Oncology

Concurrent Chemoradiotherapy for Localized Nasal Natural Killer/T-Cell Lymphoma: An Updated Analysis of the Japan Clinical Oncology Group Study JCOG0211

Motoko Yamaguchi et al.

JOURNAL OF CLINICAL ONCOLOGY (2012)

Add to Collection
Article Oncology

Clinical utility and implications of asparaginase antibodies in acute lymphoblastic leukemia

C. Liu et al.

LEUKEMIA (2012)

Add to Collection
Article Hematology

Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study

Arnaud Jaccard et al.

BLOOD (2011)

Add to Collection
Article Oncology

Failure Patterns and Clinical Implications in Early Stage Nasal Natural Killer/T-Cell Lymphoma Treated With Primary Radiotherapy

Ye-Xiong Li et al.

CANCER (2011)

Add to Collection
Article Oncology

Phase II Study of SMILE Chemotherapy for Newly Diagnosed Stage IV, Relapsed, or Refractory Extranodal Natural Killer (NK)/T-Cell Lymphoma, Nasal Type: The NK-Cell Tumor Study Group Study

Motoko Yamaguchi et al.

JOURNAL OF CLINICAL ONCOLOGY (2011)

Add to Collection
Article Oncology

Long-term outcomes of patients with newly diagnosed extranodal natural killer/T-cell lymphoma treated by etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin regimen: a single-institution experience

Huiqiang Huang et al.

LEUKEMIA & LYMPHOMA (2011)

Add to Collection
Article Oncology

Allogeneic hematopoietic stem cell transplantation for advanced extranodal natural killer/T-cell lymphoma, nasal type

Daisuke Ennishi et al.

LEUKEMIA & LYMPHOMA (2011)

Add to Collection
Article Oncology

Treatment outcome of radiotherapy alone versus radiochemotherapy in early stage nasal natural killer/T-cell lymphoma

Hui-Hui Ma et al.

MEDICAL ONCOLOGY (2010)

Add to Collection
Article Oncology

Effective second-line chemotherapy for extranodal NK/T-cell lymphoma consisting of etoposide, ifosfamide, methotrexate, and prednisolone

B. -S. Kim et al.

ANNALS OF ONCOLOGY (2009)

Add to Collection
Article Hematology

Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project

Wing-yan Au et al.

BLOOD (2009)

Add to Collection
Review Biophysics

High-dose chemotherapy and hematopoietic SCT in the management of natural killer-cell malignancies

Y. -L Kwong

BONE MARROW TRANSPLANTATION (2009)

Add to Collection
Review Oncology

Extranodal NK/T-cell lymphoma, nasal type: New staging system and treatment strategies

Tae Min Kim et al.

CANCER SCIENCE (2009)

Add to Collection
Article Oncology

Phase I/II Study of Concurrent Chemoradiotherapy for Localized Nasal Natural Killer/T-Cell Lymphoma: Japan Clinical Oncology Group Study JCOG0211

Motoko Yamaguchi et al.

JOURNAL OF CLINICAL ONCOLOGY (2009)

Add to Collection
Article Oncology

Phase II Trial of Concurrent Radiation and Weekly Cisplatin Followed by VIPD Chemotherapy in Newly Diagnosed, Stage IE to IIE, Nasal, Extranodal NK/T-Cell Lymphoma: Consortium for Improving Survival of Lymphoma Study

Seok Jin Kim et al.

JOURNAL OF CLINICAL ONCOLOGY (2009)

Add to Collection
Article Oncology

A randomized phase II study of CEOP with or without semustine as induction chemotherapy in patients with stage IE/IIE extranodal NK/T-cell lymphoma, nasal type in the upper aerodigestive tract

Xuejun Ma et al.

RADIOTHERAPY AND ONCOLOGY (2009)

Add to Collection
Article Oncology

Clinical heterogeneity of extranodal NK/T-cell lymphoma, nasal type: a national survey of the Korean Cancer Study Group

T. M. Kim et al.

ANNALS OF ONCOLOGY (2008)

Add to Collection
Article Oncology

Phase I study of dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide (SMILE) chemotherapy for advanced-stage, relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma and leukemia

Motoko Yamaguchi et al.

CANCER SCIENCE (2008)

Add to Collection
Article Oncology

Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients

Jonathan K. Armstrong et al.

CANCER (2007)

Add to Collection
Article Hematology

Pharmacodynamics and safety of intravenous pegaspargase during remission induction in adults aged 55 years or younger with newly diagnosed acute lymphoblastic leukemia

Dan Douer et al.

BLOOD (2007)

Add to Collection
Article Anatomy & Morphology

Extranodal NK/T-cell lymphoma, nasal type: Study of clinicopathologic and prognosis factors in a series of 78 cases from Peru

Carlos Barrionuevo et al.

APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY (2007)

Add to Collection
Article Oncology

Combined chemotherapy and external beam radiation for stage IE and IIE natural killer T-cell lymphoma of nasal cavity

Biyun Wang et al.

LEUKEMIA & LYMPHOMA (2007)

Add to Collection
Article Gastroenterology & Hepatology

Primary NK-/T-cell lymphoma of the gastrointestinal tract: clinical characteristics and endoscopic findings

J. H. Kim et al.

ENDOSCOPY (2007)

Add to Collection
Article Oncology

First-line ifosfamide, methotrexate, etoposide and prednisolone chemotherapy ±radiotherapy is active in stage I/II extranodal NK/T-cell lymphoma

Keun-Wook Lee et al.

LEUKEMIA & LYMPHOMA (2006)

Add to Collection
Article Oncology

Extranodal natural killer T-cell lymphoma, nasal-type: A prognostic model from a retrospective multicenter study

J Lee et al.

JOURNAL OF CLINICAL ONCOLOGY (2006)

Add to Collection
Article Oncology

Extranodal natural killer/T-cell lymphoma, nasal type - The significance of radiotherapeutic parameters

K Isobe et al.

CANCER (2006)

Add to Collection
Article Oncology

Radiotherapy as primary treatment for stage IE and IIE nasal natural Killer/T-cell lymphoma

YX Li et al.

JOURNAL OF CLINICAL ONCOLOGY (2006)

Add to Collection
Article Hematology

Local tumor invasiveness is more predictive of survival than International Prognostic Index in stage IE/IIE extranodal NK/T-cell lymphoma, nasal type

TM Kim et al.

BLOOD (2005)

Add to Collection
Article Hematology

Selective apoptosis of natural killer-cell tumours by L-asparaginase

M Ando et al.

BRITISH JOURNAL OF HAEMATOLOGY (2005)

Add to Collection
Article Hematology

Allogeneic haematopoietic stem cell transplantation as a promising treatment for natural killer-cell neoplasms

N Murashige et al.

BRITISH JOURNAL OF HAEMATOLOGY (2005)

Add to Collection
Article Oncology

Treatment outcome of angiocentric T-cell and NK/T-cell lymphoma, nasal type: Radiotherapy versus chemoradiotherapy

K Kim et al.

JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2005)

Add to Collection
Article Oncology

Radiation therapy versus chemotherapy as initial treatment for localized nasal natural killer (NK)/T-cell lymphoma: a single institute survey in Taiwan

JY You et al.

ANNALS OF ONCOLOGY (2004)

Add to Collection
Article Oncology

Treatment outcome and pattern of failure in 77 patients with sinonasal natural killer/T-cell or T-cell lymphoma

CC Li et al.

CANCER (2004)

Add to Collection
Article Oncology

Asparaginase pharmacodynamics differ by formulation among children with newly diagnosed acute lymphoblastic leukemia

LJ Hak et al.

LEUKEMIA (2004)

Add to Collection
Article Hematology

L-Asparaginase-based induction therapy for advanced extranodal NK/T-cell lymphoma

K Obama et al.

INTERNATIONAL JOURNAL OF HEMATOLOGY (2003)

Add to Collection
Article Oncology

Therapeutic outcome of extranodal NK/T-cell lymphoma initially treated with chemotherapy - Result of chemotherapy in NK/T-cell lymphoma

BS Kim et al.

ACTA ONCOLOGICA (2003)

Add to Collection
Article Hematology

L-asparaginase induced durable remission of relapsed nasal NK/T-cell lymphoma after autologous peripheral blood stem cell transplantation

K Nagafuji et al.

INTERNATIONAL JOURNAL OF HEMATOLOGY (2001)

Add to Collection
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.